Ibrutinib is also called Imbruvica is a small molecule that permanently bonds to the protein important for B cells called Bruton's tyrosine kinase. Generally, this drug is used for the treatment of B cell cancer, chronic lymphocytic leukemia, and others. This drug is categorized under targeted therapy which distinguishes the normal cells and cancer cells and slows down the growth of cancer cells. Apart from this, there are several side effects related to the drug and it is approved by the USFDA and other authorities for its treatment.
The emerging and modernizing healthcare infrastructure as well as the upsurge in the burden of chronic disorders over the period is anticipated to boost the growth of the global Ibrutinib market. Moreover, the increased prevalence of cancer coupled with technological advancement is further propel the growth of the Ibrutinib market. According to World Health Organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Additionally, other factors include favorable reimbursement scenario, growing public awareness coupled with increasing disposable income are also expected to support the market’s growth to a great extent.
On the contrary, many side effects of the ibrutinib and the high cost of the drug are anticipated to restrain the growth of the Ibrutinib market. Besides this, growth in research and development activities coupled with clinical trials and usage approvals by the authorities are projected to create ample opportunities in the Ibrutinib market in the forthcoming years.
Covid-19 Impact on Ibrutinib Market
In addition, the current Ibrutinib Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Ibrutinib Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.
The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.
Ibrutinib Market Segment Overview
Based on Application, Chronic Lymphocytic Leukaemia (CLL) is the major segment in the global Ibrutinib market. Chronic Lymphocytic Leukaemia (CLL) is a type of cancer that starts in cells that become certain white blood cells (called lymphocytes) in the bone marrow. In CLL, the leukemia cells often build up slowly. Many people don't have any symptoms for at least a few years. But over time, the cells grow and spread to other parts of the body, including the lymph nodes, liver, and spleen. Furthermore, Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western populations and comprises 25 to 30 percent of leukemias in the United States. This activity reviews the evaluation and management of chronic lymphocytic leukemia and highlights the role of interprofessional team members in collaborating to provide well-coordinated care and enhance outcomes for affected patients.
Ibrutinib Market, By Product Type
· 140 mg
· 10 mg
· 5 mg
Ibrutinib Market, By Application
· Chronic Lymphocytic Leukaemia (CLL)
· Mantle Cell Lymphoma (MCL)
· Diffuse Large B Cell Lymphoma (DLBCL)
· Multiple Myeloma (MM)
· Follicular Lymphoma (FL)
Ibrutinib Market Regional Overview
In terms of region, North America commanded a major share of the Ibrutinib market and is predictable to maintain its supremacy over the forecast period. This is attributable to factors including the presence of well-established healthcare facilities, increased prevalence of cancer, usage approvals by the authorities, and technological advancements. Similarly, the market in the Asia-Pacific is expected to witness significant growth in the forthcoming period. The emerging healthcare facilities, favorable reimbursement scenario, and growing awareness about diseases and treatments are some important factors that majorly contribute to the development of the Ibrutinib market over the forecast period.
Ibrutinib Market, By Geography
· North America (US & Canada)
· Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
· Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
· LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
Ibrutinib Market Competitor overview
Some key developments and strategies adopted by manufacturers in Ibrutinib are highlighted below.
· In August 2021, Natco Pharma has lost a legal battle with Pharmacyclics, a subsidiary of AbbVie over the patent of anti-cancer drug Imbruvica in the United States.
Ibrutinib Market, Key Players
· Beacon Pharmaceuticals
· Janssen Pharmaceuticals
· Pharmacyclics Inc.
· Johnson and Johnson
· Incepta Pharmaceuticals
· Bluepharma
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
4. Key Insights
- 4.1. Key Emerging Trends – For Major Countries
- 4.2. Latest Technological Advancement
- 4.3. Regulatory Landscape
- 4.4. Industry SWOT Analysis
- 4.5. Porters Five Forces Analysis
5. Global Ibrutinib Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 5.1. Key Findings / Summary
- 5.2. Market Analysis, Insights and Forecast – By Product Type
- 5.2.1. 140 mg
- 5.2.2. 10 mg
- 5.2.3. 5 mg
- 5.3. Market Analysis, Insights and Forecast – By Application
- 5.3.1. Chronic Lymphocytic Leukaemia (CLL)
- 5.3.2. Mantle Cell Lymphoma (MCL)
- 5.3.3. Diffuse Large B Cell Lymphoma (DLBCL)
- 5.3.4. Multiple Myeloma (MM)
- 5.3.5. Follicular Lymphoma (FL)
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America, Middle East and Africa
6. North America Ibrutinib Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 6.1. Key Findings / Summary
- 6.2. Market Analysis, Insights and Forecast – By Product Type
- 6.2.1. 140 mg
- 6.2.2. 10 mg
- 6.2.3. 5 mg
- 6.3. Market Analysis, Insights and Forecast – By Application
- 6.3.1. Chronic Lymphocytic Leukaemia (CLL)
- 6.3.2. Mantle Cell Lymphoma (MCL)
- 6.3.3. Diffuse Large B Cell Lymphoma (DLBCL)
- 6.3.4. Multiple Myeloma (MM)
- 6.3.5. Follicular Lymphoma (FL)
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Ibrutinib Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 7.1. Key Findings / Summary
- 7.2. Market Analysis, Insights and Forecast – By Product Type
- 7.2.1. 140 mg
- 7.2.2. 10 mg
- 7.2.3. 5 mg
- 7.3. Market Analysis, Insights and Forecast – By Application
- 7.3.1. Chronic Lymphocytic Leukaemia (CLL)
- 7.3.2. Mantle Cell Lymphoma (MCL)
- 7.3.3. Diffuse Large B Cell Lymphoma (DLBCL)
- 7.3.4. Multiple Myeloma (MM)
- 7.3.5. Follicular Lymphoma (FL)
- 7.4. Market Analysis, Insights and Forecast – By Country
- 7.4.1. UK
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Russia
- 7.4.7. Rest of Europe
8. Asia Pacific Ibrutinib Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 8.1. Key Findings / Summary
- 8.2. Market Analysis, Insights and Forecast – By Product Type
- 8.2.1. 140 mg
- 8.2.2. 10 mg
- 8.2.3. 5 mg
- 8.3. Market Analysis, Insights and Forecast – By Application
- 8.3.1. Chronic Lymphocytic Leukaemia (CLL)
- 8.3.2. Mantle Cell Lymphoma (MCL)
- 8.3.3. Diffuse Large B Cell Lymphoma (DLBCL)
- 8.3.4. Multiple Myeloma (MM)
- 8.3.5. Follicular Lymphoma (FL)
- 8.4. Market Analysis, Insights and Forecast – By Country
- 8.4.1. China
- 8.4.2. India
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. South East Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America, Middle East and Africa Ibrutinib Market Analysis (USD Billion), Insights and Forecast, 2020-2027
- 9.1. Key Findings / Summary
- 9.2. Market Analysis, Insights and Forecast – By Product Type
- 9.2.1. 140 mg
- 9.2.2. 10 mg
- 9.2.3. 5 mg
- 9.3. Market Analysis, Insights and Forecast – By Application
- 9.3.1. Chronic Lymphocytic Leukaemia (CLL)
- 9.3.2. Mantle Cell Lymphoma (MCL)
- 9.3.3. Diffuse Large B Cell Lymphoma (DLBCL)
- 9.3.4. Multiple Myeloma (MM)
- 9.3.5. Follicular Lymphoma (FL)
- 9.4. Market Analysis, Insights and Forecast – By Country
- 9.4.1. Brazil
- 9.4.2. Saudi Arabia
- 9.4.3. UAE
- 9.4.4. Rest of LAMEA
10. Competitive Analysis
- 10.1. Company Market Share Analysis, 2018
- 10.2. Key Industry Developments
- 10.3. Company Profile
- 10.4. Beacon Pharmaceuticals
- 10.4.1. Business Overview
- 10.4.2. Segment 1 & Service Offering
- 10.4.3. Overall Revenue
- 10.4.4. Geographic Presence
- 10.4.5. Recent Development
- 10.5. Janssen Pharmaceuticals
- 10.6. Pharmacyclics Inc.
- 10.7. Johnson and Johnson
- 10.8. Incepta Pharmaceuticals
Data Library Research are conducted by industry experts who offer insight on industry structure, market segmentations technology assessment and competitive landscape (CL), and penetration, as well as on emerging trends. Their analysis is based on primary interviews (~ 80%) and secondary research (~ 20%) as well as years of professional expertise in their respective industries. Adding to this, by analysing historical trends and current market positions, our analysts predict where the market will be headed for the next five years. Furthermore, the varying trends of segment & categories geographically presented are also studied and the estimated based on the primary & secondary research.
In this particular report from the supply side Data Library Research has conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and SOFT) of the companies that active & prominent as well as the midsized organization
FIGURE 1: DLR RESEARH PROCESS
Extensive primary research was conducted to gain a deeper insight of the market and industry performance. The analysis is based on both primary and secondary research as well as years of professional expertise in the respective industries.
In addition to analysing current and historical trends, our analysts predict where the market is headed over the next five years.
It varies by segment for these categories geographically presented in the list of market tables. Speaking about this particular report we have conducted primary surveys (interviews) with the key level executives (VP, CEO’s, Marketing Director, Business Development Manager and many more) of the major players active in the market.
Secondary ResearchSecondary research was mainly used to collect and identify information useful for the extensive, technical, market-oriented, and Friend’s study of the Global Extra Neutral Alcohol. It was also used to obtain key information about major players, market classification and segmentation according to the industry trends, geographical markets, and developments related to the market and technology perspectives. For this study, analysts have gathered information from various credible sources, such as annual reports, sec filings, journals, white papers, SOFT presentations, and company web sites.
Market Size EstimationBoth, top-down and bottom-up approaches were used to estimate and validate the size of the Global market and to estimate the size of various other dependent submarkets in the overall Extra Neutral Alcohol. The key players in the market were identified through secondary research and their market contributions in the respective geographies were determined through primary and secondary research.
Forecast Model
